ViroGates A/S
CSE:VIRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ViroGates A/S
Cash & Cash Equivalents
ViroGates A/S
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
ViroGates A/S
CSE:VIRO
|
Cash & Cash Equivalents
kr26.3m
|
CAGR 3-Years
39%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
Cash & Cash Equivalents
kr1.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
24%
|
|
|
Ambu A/S
CSE:AMBU B
|
Cash & Cash Equivalents
kr735m
|
CAGR 3-Years
80%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Demant A/S
CSE:DEMANT
|
Cash & Cash Equivalents
kr1.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
ViroGates A/S
Glance View
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
See Also
What is ViroGates A/S's Cash & Cash Equivalents?
Cash & Cash Equivalents
26.3m
DKK
Based on the financial report for Dec 31, 2025, ViroGates A/S's Cash & Cash Equivalents amounts to 26.3m DKK.
What is ViroGates A/S's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-5%
Over the last year, the Cash & Cash Equivalents growth was 115%. The average annual Cash & Cash Equivalents growth rates for ViroGates A/S have been 39% over the past three years , -5% over the past five years .
